

SEPTEMBER 2026 QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C

AML3D Limited (ASX: AL3) ("AML3D" or "the Company"), a leader in large scale Wire Additive Manufacturing ("WAM[®]") technology and 3D metal printing solutions, is pleased to provide the Quarterly Activities Report and Appendix 4C for the quarter ended 30 September 2026 (1Q27).

KEY HIGHLIGHTS DURING THE QUARTER

AML3D's primary focus in 1Q27 has been progress against its substantial order book. The company's manufacturing base is working hard to progress the \$16.8 million of orders that rolled over into FY27, an 87% improvement on the \$9 million of orders that rolled over into FY26. AML3D's global sales pipeline continues to expand and is now more than \$80 million. 1Q27 Customer receipts of \$3 million are up 19% on the prior comparable period.

Key highlights from the quarter include:

- A first **US Navy nuclear submarines production parts** order from Austal USA Advanced Technologies valued at **~AU\$0.5 million** for the supply of high pressure, fluid control components.
- Joining a **global aerospace prime** and research partners to launch a **3-year, \$3.9 million R&D project** to develop AML3D's **Wire-Arc Additive Manufacturing technology for Aerospace** applications.

GROWTH STRATEGY

US scale up

The continuing success of AML3D's US scale up strategy remains the Company's primary growth driver. Manufacturing at our US Technology Centre at Stow Ohio, is focussed on the \$16.8 million of orders that rolled into 1Q27. AML3D's largest ever ARCEMY[®] order, a \$9.9 million contract for four large scale ARCEMY[®] X systems by Newport News Shipbuilding ("NNS"), is tracking for on time delivery in 2Q27. NNS is a division of Huntington Ingalls Industries, the largest military ship builder in the USA and a prime supplier to Navy Maritime Industrial Base (MIB). The MIB includes submarines, aircraft carriers, surface ships, and munitions. The 4 ARCEMY[®] X systems order doubles the previous NNS systems order and is representative of the growing demand that has driven AML3D's global order pipeline to a record of over \$80 million.

The evolution of component manufacturing from qualification programs to production parts in the US was demonstrated during 1Q27 by AML3D announcing an initial US Nuclear Submarine Industrial Base ("SIB") production parts order. Austal USA Advanced Technologies placed an order for three large, high pressure, fluid control submarine components signalling a shift in procurement from traditional manufacturing to AML3D's advanced Wire-Arc Additive Manufacturing.



It follows a second order for five high demand, non-safety critical replacement components for US Navy submarines placed by BlueForge Alliance, a non-profit US Defence industrial base optimisation agency, that are already in production. These five high demand complex components are no longer supported by the original equipment manufacturer and are tracking for on time delivery in the second half of the current financial year. AML3D received a letter of Intent from the US Navy in FY26 indicating the need for up to 1600 additively manufacturing components by 2030.

The change in the value and volume of the ARCEMY® system orders supporting the US MIB and transition to manufacturing production parts for the US Navy SIB during the quarter supports AML3D's ongoing \$12 million investment to double US manufacturing capacity to meet this increasing demand.

Australia

AML3D's Australian facilities provide manufacturing capacity and Research and Development capabilities that ensure AML3D retains its competitive edge as a leader in advanced additive manufacturing technology.

During the quarter AML3D joined a global aerospace prime and industry and research partners in a 3-year, \$3.9 million, advanced manufacturing for the Aerospace sector project. AML3D will contribute approximately \$0.5 million, made up of \$130,000 in cash and \$400,000 in staff and other in-kind contributions, over the project term. The aim of the project is to develop AML3D's WAM® technology to a level suitable for qualified Aerospace tooling production applications. AML3D's participation in the R&D project is not expected to generate revenue directly, but a successful conclusion to the project will position the company as a potential Aerospace tooling production supplier, potentially creating new high value, Aerospace revenue opportunities. The project is consistent with AML3D's medium term growth ambitions to access additional, globally significant, industrial manufacturing markets.

AML3D is already recognised by Austrade as one of the largest exporters under the tri-lateral AUKUS defence pact, The ARCEMY® advanced manufacturing footprint in Australia includes Perth and Adelaide, where the Australian Government is making multibillion dollar investments in AUKUS infrastructure and sustainment capabilities. The proximity of ARCEMY® systems to these AUKUS hubs means AML3D is well positioned to demonstrate how its additive manufacturing technology can be used to support the Royal Australian Navy's contribution to AUKUS. AML3D Australia also plans to leverage the relationships of Board Advisor and former AUKUS specialist, Rear Admiral David Goggins, to secure additional Royal Australian Navy contracts over time.

AML3D's Australian Technology Centre at North Plympton in Adelaide is delivering AML3D's UK contracts and provides additional capacity to help scale up manufacturing to meet accelerating demand in the US. AML3D's Australian operations will also support emerging demand in Europe and other globally significant industrial manufacturing markets.

UK, Europe & the Rest of the World

During the quarter AML3D continued the \$1.2 million material feasibility and test block program for UK Defence supplier, BAE Systems UK and component manufacturing for a UK defence prime supplier. The Company also continued negotiations for an initial European ARCEMY® system installation. Deploying ARCEMY® technology to Europe will create a global network of ARCEMY® systems geographically aligned to the AUKUS defence partners of the UK, Australia and the USA.

AML3D has identified strong demand signals emerging in additional, globally significant, industrial manufacturing markets across the Middle East and Southeast Asia. In combination the UK, Europe, the Middle East and Southeast Asia form AML3D's Rest of the World markets ("ROW"). To ensure AML3D can respond effectively to this emerging ROW demand the Company has pre-allocated \$5 million of funding to establish a new Technology Centre to provide additional advanced additive manufacturing capacity. The new Technology centre will be designed to allow AML3D to be more responsive to the needs of AUKUS partner, the UK's, defence industrial base. It is also expected to further minimise the lead times on European defence and industrial manufacturing contracts as they emerge and accelerate AML3D's ability



to meet demand from additional ROW markets. The evolving ROW demand signals will be a key consideration when determining the location of the new, fully funded, \$5 million ROW Technology Centre.

FINANCIAL UPDATE

AML3D had cash receipts of \$3.0 million in the September 2026 quarter, compared to \$2.5 million in the PCP, a rise of 19%.

Product manufacturing and operating costs of \$2.5 million, were up 200% from \$0.76 million in the PCP reflecting the significant increase in order volumes resulting from the success of AML3D's US scale up strategy, including the largest ever single ARCEMY® defence order for four ARCEMY® X systems for Newport News Shipbuilding for delivery in 2Q27. Net cash used in operating activities was \$2.13 million up from \$0.59 million in the PCP.

The company's cash position remains strong at \$24.42 million, on 30 September 2026. AML3D retains the balance sheet strength to continue the \$12 million investment to double capacity within the Company's US operations and establish a new, \$5 million, Technology Centre to support emerging ROW demand.

OUTLOOK

AML3D focussed on progressing orders in hand in 1Q27 to deliver short term value. The \$9.9 million order for 4 ARCEMY® X systems from NNS is tracking for on time delivery in Q2, while the \$2.61 million order for high demand, non-safety critical components for in service trials on US Navy submarines and the initial US Navy submarine production parts order are tracking for on time delivery in Q3.

In addition to delivering the record \$16.8 million of orders in hand, that rolled over into FY27, AML3D will continue work on converting the global sales pipeline, which stands at more than \$80 million, into new orders to deliver additional medium-term value. To keep pace with the strong and growing demand in USA and emerging demand in multiple ROW markets, in both defence and industrial manufacturing, AML3D will continue its fully funded investment programs to double US manufacturing capacity and establish a new Technology Centre to support the ROW markets.

The creation of a global network of AML3D technology centres, aligned to support the trilateral AUKUS partners of Australia, the UK and the USA as well as additional high value industrial manufacturing markets is expected to be a significant medium to longer term driver of revenue and value creation.

This announcement has been authorised for release by the Board of AML3D.

For further information, please contact:

Sean Ebert
Chief Executive Officer

AML3D Limited

T: +61 429 550 593

E: investor@aml3d.com

Hamish McEwin
Chief Financial Officer

AML3D Limited

T: +61 429 550 593

E: investor@aml3d.com



About AML3D Limited

AML3D Limited, a publicly listed technology company founded in 2014, is disrupting metal part supply chains using the Company's patented Wire Additive Manufacturing (WAM®) process. WAM® combines state-of-the-art welding science, robotics automation, materials engineering and proprietary software to lead metal additive manufacturing globally. AML3D is the OEM of the ARCEMY® industrial metal 3D printing systems. ARCEMY® uses WAM® to provide advanced, automated, on-demand, point-of-need 3D manufacturing solutions that are more efficient, cost-effective and have better ESG outcomes compared to traditional casting, forging and billet machining processes. ARCEMY® is IIoT and Industry 4.0 enabled to allow manufacturers across Aerospace, Defence, Maritime, Manufacturing, Mining and Oil & Gas to become globally competitive. AML3D also provides metal 3D printing design engineering services, software licencing, technical support, consumable sales and contract manufacturing services.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AML3D Limited

ABN

55 602 857 983

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	2,969	2,969
1.2 Payments for		
(a) research and development	(298)	(298)
(b) product manufacturing and operating costs	(2,455)	(2,455)
(c) advertising and marketing	(44)	(44)
(d) leased assets	-	-
(e) staff costs	(2,047)	(2,047)
(f) administration and corporate costs	(1,319)	(1,319)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	276	276
1.5 Interest and other costs of finance paid	(34)	(34)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	821	821
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(2,131)	(2,131)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(115)	(115)
(d) investments	(20,000)	(20,000)
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	20,000	20,000
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(115)	(115)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	60	60
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(60)	(60)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	-

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	26,670	26,670
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,131)	(2,131)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(115)	(115)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	(4)	(4)
4.6	Cash and cash equivalents at end of period	24,420	24,420

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	4,420	6,670
5.2	Call deposits	20,000	20,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	24,420	26,670

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	-
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	N/A		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,131)
8.2	Cash and cash equivalents at quarter end (item 4.6)	24,420
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	24,420
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	11
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 23 October 2026

Authorised by: the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.